<table>
<thead>
<tr>
<th><strong>Cell Line Designation</strong></th>
<th>MM253</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CellBank Catalogue No.</strong></td>
<td>CBA-1347</td>
</tr>
<tr>
<td><strong>Lot Number</strong></td>
<td>13470810G</td>
</tr>
<tr>
<td><strong>Passage Number</strong></td>
<td>+ 10</td>
</tr>
<tr>
<td><strong>Total Cell Number</strong></td>
<td>$3.0 \times 10^6$ cells</td>
</tr>
<tr>
<td><strong>Expected Cell Viability</strong></td>
<td>94.8% at thaw</td>
</tr>
</tbody>
</table>

**Brief Description**
Melanoma; from metastatic site - Lymph node

**Organism**
Human (*Homo Sapiens*)

**Tissue**
Skin, metastatic site - lymph node

**Growth Properties**
Adherent

**Morphology**
Epithelial

**Growth Medium**
RPMI 1640 (with 2mM L-Glutamine+25mM HEPES) +10% FBS

**Subcultivation Ratio**
Split sub-confluent flasks (70-80%). Optimal split ratio 1:4-1:8 using 0.05% Trypsin/EDTA at 37°C for 5 min. Seeding density $0.8 \times 10^4$ cells/cm².

**Establishing and Maintaining your Culture**
Cells incubated at 37°C with 5% CO₂.

**Cryoprotectant Medium**
10% DMSO + 90% FCS.
Safety Precaution

Where cell lines are shipped as frozen ampoules there is a small risk that the ampoule may be pressurised, due to the expansion of trapped liquid nitrogen and could explode on warming. It is recommended that persons handling ampoules of frozen cells wear appropriate personal protective equipment including laboratory coat, insulated gloves and a full protective face shield.

Biosafety Level.

Cell line of human origin. CellBank Australia recommends that cell lines be handled at category PC-2* containment level.

*AS/NZS 2243.3:2010

Handling Procedure for Frozen Cells

Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability. Remove protective cryoflex layer around the ampoule prior to thawing. A precentrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.

Use Restrictions

These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).

Additional Information

Homozygous deletion p14ARF and p16INK4A V599E mutations BRAF

Depositor

Peter Parsons
Queensland Institute of Medical Research, Australia

References

P. G. Parsons, Leanne Morrison Melphalan-induced chromosome damage in sensitive and resistant human melanoma cell lines International Journal of Cancer 21:(4) 407 - 522, 1978


CellBank Warranty

While CellBank Australia uses reasonable efforts to include accurate and up-to date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.
Disclaimers

This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures.

Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com